ロード中...
Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment in multiple myeloma. Pulmonary complications are believed to be rare, especia...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Yonsei University College of Medicine
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2852803/ https://ncbi.nlm.nih.gov/pubmed/20376900 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2010.51.3.448 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|